76 related articles for article (PubMed ID: 12241641)
1. Anti-inflammatory effect of cerivastatin in vascular injury independent of serum cholesterol and blood pressure lowering effects in mouse model.
Chen X; Li Z; Li J
Chin J Traumatol; 2002 Oct; 5(5):294-8. PubMed ID: 12241641
[TBL] [Abstract][Full Text] [Related]
2. Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha and improves vascular remodeling after vascular injury in mouse.
Li Z; Chen XD; Ni SK; Li JW; Lin MS
Chin J Traumatol; 2004 Feb; 7(1):56-61. PubMed ID: 14728822
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
[TBL] [Abstract][Full Text] [Related]
4. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators.
Kizu A; Shioi A; Jono S; Koyama H; Okuno Y; Nishizawa Y
J Cell Biochem; 2004 Nov; 93(5):1011-9. PubMed ID: 15389884
[TBL] [Abstract][Full Text] [Related]
5. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
Park JK; Müller DN; Mervaala EM; Dechend R; Fiebeler A; Schmidt F; Bieringer M; Schäfer O; Lindschau C; Schneider W; Ganten D; Luft FC; Haller H
Kidney Int; 2000 Oct; 58(4):1420-30. PubMed ID: 11012877
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Chen Y; Ku H; Zhao L; Wheeler DC; Li LC; Li Q; Varghese Z; Moorhead JF; Powis SH; Huang A; Ruan XZ
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):365-76. PubMed ID: 24233489
[TBL] [Abstract][Full Text] [Related]
7. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
[TBL] [Abstract][Full Text] [Related]
8. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.
Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O
Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218
[TBL] [Abstract][Full Text] [Related]
9. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis.
Ando H; Takamura T; Ota T; Nagai Y; Kobayashi K
J Pharmacol Exp Ther; 2000 Sep; 294(3):1043-6. PubMed ID: 10945857
[TBL] [Abstract][Full Text] [Related]
10. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance.
Chaudhry MZ; Wang JH; Blankson S; Redmond HP
Surg Infect (Larchmt); 2008 Apr; 9(2):183-94. PubMed ID: 18426351
[TBL] [Abstract][Full Text] [Related]
11. Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury.
Shishido T; Nozaki N; Takahashi H; Arimoto T; Niizeki T; Koyama Y; Abe J; Takeishi Y; Kubota I
Biochem Biophys Res Commun; 2006 Jul; 345(4):1446-53. PubMed ID: 16730663
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin inhibits myocardin expression in vascular smooth muscle cells.
Li J; Jiang J; Yin H; Wang L; Tian R; Li H; Wang Z; Li D; Wang Y; Gui Y; Walsh MP; Zheng XL
Hypertension; 2012 Jul; 60(1):145-53. PubMed ID: 22615115
[TBL] [Abstract][Full Text] [Related]
13. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.
Sata M; Nishimatsu H; Suzuki E; Sugiura S; Yoshizumi M; Ouchi Y; Hirata Y; Nagai R
FASEB J; 2001 Nov; 15(13):2530-2. PubMed ID: 11641268
[TBL] [Abstract][Full Text] [Related]
14. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures.
Axel DI; Riessen R; Runge H; Viebahn R; Karsch KR
J Cardiovasc Pharmacol; 2000 Apr; 35(4):619-29. PubMed ID: 10774794
[TBL] [Abstract][Full Text] [Related]
15. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.
Shiomi M; Ito T
Br J Pharmacol; 1999 Feb; 126(4):961-8. PubMed ID: 10193776
[TBL] [Abstract][Full Text] [Related]
16. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects.
Omori H; Nagashima H; Tsurumi Y; Takagi A; Ishizuka N; Hagiwara N; Kawana M; Kasanuki H
Br J Clin Pharmacol; 2002 Oct; 54(4):395-9. PubMed ID: 12392587
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor.
Chen J; Zhang J; Xu L; Xu C; Chen S; Yang J; Jiang H
Atherosclerosis; 2012 Oct; 224(2):332-9. PubMed ID: 22857898
[TBL] [Abstract][Full Text] [Related]
18. Aging exacerbates neointimal formation, and increases proliferation and reduces susceptibility to apoptosis of vascular smooth muscle cells in mice.
Vazquez-Padron RI; Lasko D; Li S; Louis L; Pestana IA; Pang M; Liotta C; Fornoni A; Aitouche A; Pham SM
J Vasc Surg; 2004 Dec; 40(6):1199-207. PubMed ID: 15622375
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression.
Xu Y; Zhou S; Fang Z; Li X; Huang D; Liu Q; Zheng C
Pharm Biol; 2014 Sep; 52(9):1196-203. PubMed ID: 25116077
[TBL] [Abstract][Full Text] [Related]
20. The role of Rho-associated kinase in differential regulation by statins of interleukin-1beta- and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells.
Wei CY; Huang KC; Chou YH; Hsieh PF; Lin KH; Lin WW
Mol Pharmacol; 2006 Mar; 69(3):960-7. PubMed ID: 16317111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
